HYDERABAD: State director general of Drug Administration has sought a CBI probe into the administration of Abhay-M measles vaccine that led to a spate of deaths of innocent children across the country.
R P Meena, the DG of Drug Administration, made this appeal to the AP High Court in an affidavit filed against a drug manufacturing company, M/s Human Biologicals Institute, which is a division of Indian Immunologicals Ltd based in Gachibowli. Abhay-M is one of the vaccines being manufactured and sold by the company.
Upon complaints and media reports about the death of children of poorer sections, the authorities of both the state and central drug wings conducted a joint inspection of the premises of the company on March 17, 21 and 23 of 2011 and found several serious lapses in the way the vaccine was made and the raw materials being stored in the company. Accordingly, the drug administration authorities had ordered the company to stop the production.
According to the DG’s affidavit, upon coming to know of the order, the Drug Controller General of India has sent a team from Delhi with a clear message that they should inspect the company once again and give a clean chit to it. Accordingly, the central team arrived and took the state drug administration authorities also along with it and reinspected the premises on April 7, 2011. Even though none of the discrepancies were set right by the company, the central team gave a clean chit to it. The state officials refused to accept this sudden U-turn by the central authorities.
[Note from SaneVax: Thanks to India for bringing this information out in the open. The SaneVax Team is dedicated to exposing this type of tactic any time it comes to our attention. Companies and government agencies responsible for public health decisions must be held accountable for the decisions they make.
Safe, Affordable, Necessary and Effective vaccination practices depend on accurate scientific information, transparency throughout the development, approval, manufacturing and distribution chain, and ethical standards each step of the way. Medical consumers around the world deserve nothing less. It is time for them to demand what they deserve. After all, if pharmaceutical manufacturers are producing products that live up to the claims being made, there will be no problem obtaining sales – customers will be beating a path to their door.